Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242268 | 0.85 | — | — | |
| Trifluoroacetic Acid SCHEMBL28163815 | 0.83 | PKM (0.48) | PKMCA2CA12CA1CA9 | |
| Benzene SCHEMBL28638889 | 0.83 | SIGMAR1 (0.53) | CA2CA12CA1CA9CHKA | |
| Oxalic Acid SCHEMBL10413766 | 0.83 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| Water SCHEMBL15152290 | 0.83 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL8029418 | 0.83 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| Bromide SCHEMBL21957301 | 0.83 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL21065355 | 0.83 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL956960 | 0.83 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL28709291 | 0.83 | CA2 (0.52) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3100723-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2442644-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| CN-102480943-A | Opsin binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC | 2012-05-30 | — | — | CN | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010147653-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, UACA | PKM 4226/4885CA2 2704/4885CA12 4576/4885 |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | PKM 4226/4885CA2 2704/4885CA12 4576/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PKM 1961/4885CA2 3666/4885CA12 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.